**Table e-1. Clinical manifestations reported in patients with the investigated CD59 mutations.**

|  |  |  |
| --- | --- | --- |
| Mutation (in parentheses: numbering after processing) | Reference | Clinical manifestations |
| Hemolytic anemia | Recurrent peripheral neuropathy | Recurrent strokes |
| Cys64Tyr (89) (point mutation, missense) | Ben-Zeev et al., 2015;[5](#_ENREF_5) Nevo et al., 2013[4](#_ENREF_4) | 7/7 | 7/7 | 2/7 |
| Asp24Val (49) (point mutation, missense) | Haliloglu et al., 2015[9](#_ENREF_9) | 3/3 | 3/3 | 2/3 |
| Asp24Val*fs* (49) (deletion, frameshift, stop codon) | Hochsmann et al., 2014;[8](#_ENREF_8) Ardicli et al, 2017[7](#_ENREF_7) | 2/2 | 2/2 | 2/2 |
| Ala16Ala*fs* (41)(Two deletions at positions 16 and 96. The first leads to frameshift and stop codon after 53 (79) residues) | Motoyama et al., 1992[11](#_ENREF_11) | 1/1 | 0/1 | 1/1 |
| All patients carrying one of the four mutations |  | 13/13 | 12/13 | 7/13 |

**Table e-2. Detection of wild type (WT) and mutated hCD59 by monoclonal and polyclonal antibodies**

|  |  |  |  |
| --- | --- | --- | --- |
| Antibodies / Mutation | MEM43, HC1, BRIC229, 1.39, and Rabbit polyclonal | A35 and YTH53.1 | Myc antibody |
| CD59 WT | + (fluorescent microscopy and flow cytometry) | + (flow cytometry) | + (fluorescent microscopy and flow cytometry) |
| Missense mutations Cys64Tyr, Asp24Val | -  | -  | + |
| Frameshift mutations Asp24Val*fs*\*, Ala16Ala*fs*\* | -  | -  | - |